745052-92-0

Usage

Uses

Used in Organic Synthesis:
Triphenyl[(tetrahydro-2H-pyran-4-yl)methyl]phosphonium iodide is used as a phase-transfer catalyst for enhancing the efficiency of various organic reactions. Its ability to transfer reactants between immiscible phases allows for improved reaction rates and yields, making it a valuable tool for synthetic chemists.
Used in Nucleophilic Substitution Reactions:
In the field of organic chemistry, Triphenyl[(tetrahydro-2H-pyran-4-yl)methyl]phosphonium iodide serves as a catalyst in nucleophilic substitution reactions. It aids in the reaction process by transferring nucleophiles from one phase to another, thus increasing the reaction rate and improving the overall yield of the desired product.
Used in Wittig-Type Reactions:
Triphenyl[(tetrahydro-2H-pyran-4-yl)methyl]phosphonium iodide is also utilized as a catalyst in Wittig-type reactions, which are crucial for the synthesis of various complex organic molecules. Its catalytic action in these reactions contributes to the formation of the desired products with higher yields and efficiency.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Triphenyl[(tetrahydro-2H-pyran-4-yl)methyl]phosphonium iodide is employed as a catalyst in the synthesis of various drug molecules. Its ability to facilitate reactions between different phases allows for the efficient production of complex pharmaceutical compounds, contributing to the development of new and improved medications.
Used in Material Science:
In material science, Triphenyl[(tetrahydro-2H-pyran-4-yl)methyl]phosphonium iodide is used as a catalyst for the synthesis of advanced materials, such as polymers and composites. Its phase-transfer catalytic properties enable the production of materials with specific properties and improved performance, making it a valuable component in the development of innovative materials for various applications.

Upstream product

• 101691-94-5 4-(iodomethyl)tetrahydro-2H-pyran 
• 603-35-0 triphenylphosphine 
• 14774-37-9 (tetrahydro-2H-pyran-4-yl)methanol 
• 101691-65-0 toluene-4-sulfonic acid tetrahydropyran-4-ylmethyl ester 

Downstream Products

• 745052-98-6 (E)-2-(4-(cyclopropylsulfonyl)phenyl)-3-(tetrahydro-2H-pyran-4-yl)acrylic acid 
• 1397795-19-5 (E)-ethyl 2-(4-(cyclopropylthio)phenyl)-3-(tetrahydro-2H-pyran-4-yl)acrylate 
• 1397795-26-4 (Z)-ethyl 2-(4-(cyclopropylthio)phenyl)-3-(tetrahydro-2H-pyran-4-yl)acrylate 
• 745052-96-4 ethyl 2-(4-(cyclopropylsulfonyl)phenyl)-3-(tetrahydro-2H-pyran-4-yl)acrylate 
• 745052-95-3 ethyl 2-(4-(cyclopropylthio)phenyl)-3-(tetrahydro-2H-pyran-4-yl)acrylate 
• 1174229-16-3 ethyl 2-[3-bromo-4-(cyclopropylsulfanyl)phenyl]-3-(tetrahydro-2H-pyran-4-yl)acrylate 

Relevant academic research and scientific papers

CONDENSED RING HETEROCYCLIC COMPOUND

The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like. [wherein, R1 represents optionally substituted lower alkyl and the like, R2 represents optionally substituted lower alkyl and the like, R3 represents the formula (II): (wherein, n represents 0 or 1, R3a represents a hydrogen atom and the like, R3b represents a hydrogen atom and the like, and R3c represents a hydrogen atom and the like) and the like, Q represents a hydrogen atom and the like, and W1 represents a nitrogen atom and the like, W2 represents a nitrogen atom and the like]

SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: Discovery of PSN-GK1

Allosteric activators of the glucose-sensing enzyme glucokinase (GK) are currently attracting much interest as potential antidiabetic therapies because they can achieve powerful blood glucose lowering through actions in multiple organs. Here, the optimization of a weakly active high-throughput screening hit to (2R)-2-(4-cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydropyran-4-yl)propionamide (PSN-GK1), a potent GK activator with an improved pharmacokinetic and safety profile, is described. Following oral administration, this compound elicited robust glucose lowering in rats.

TRICYCLO SUBSTITUTED AMIDES

Compounds of Formula (I) or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.

ENANTIOSELECTIVE PROCESS

A process for the production of compounds comprising the enantioselective hydrogenation of 2-substituted acrylic acid derivatives.

FLUORINATION PROCESS OF PROTECTED AMINOTHIAZOLE

A process for the production of fluorinated compound formula (I) comprising fluorination of a protected aminothiazole. Compounds formula (I) are useful in the preparation of activators of glucokinase.

TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS

Compounds of Formula (I): or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.

TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS

Compounds of Formula (I): (I) or pharmaceutically acceptable salts or N-oxides thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.